Advanced Drug Delivery Systems: New Developments, New Technologies

Published by: BCC Research

Published: Aug. 1, 2009 - 200 Pages

Table of Contents

CHAPTER ONE: INTRODUCTION

STUDY OBJECTIVES

REASONS FOR DOING THIS STUDY

INTENDED AUDIENCE

SCOPE OF THE STUDY

METHODOLOGY

INFORMATION SOURCES

ABOUT THE AUTHOR

RELATED BCC REPORTS

BCC ONLINE SERVICES

DISCLAIMER

CHAPTER TWO: SUMMARY

SUMMARY TABLE GLOBAL SALES FOR DRUG DELIVERY PRODUCTS, THROUGH 2014 ($ BILLIONS)

SUMMARY FIGURE GLOBAL SALES FOR DRUG DELIVERY PRODUCTS, 2007-2014 ($ BILLIONS)

CHAPTER THREE: OVERVIEW

DEFINITIONS

NEED FOR THE DOSAGE FORMS

CLASSIFICATION OF DOSAGE FORMS ACCORDING TO PHYSICAL PROPERTIES

GASEOUS DOSAGE FORMS

TABLE 1 GASEOUS DOSAGE FORMS, ADVANTAGES AND DISADVANTAGES

LIQUID DOSAGE FORMS

TABLE 2 LIQUID DOSAGE FORMS, ADVANTAGES AND DISADVANTAGES

SEMISOLID DOSAGE FORMS

TABLE 3 SEMISOLID DOSAGE FORMS, ADVANTAGES AND DISADVANTAGES

SOLID DOSAGE FORMS

TABLE 4 SOLID DOSAGE FORMS, ADVANTAGES AND DISADVANTAGES

CLASSIFICATION OF DRUG DELIVERY ACCORDING TO ROUTE OF ADMINISTRATION

TOPICAL DRUG DELIVERY

TABLE 5 TOPICAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES

ORAL DRUG DELIVERY

TABLE 6 ORAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES

INJECTABLE OR PARENTERAL DRUG DELIVERY

TABLE 7 INJECTABLE OR PARENTERAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES

RECTAL DRUG DELIVERY

TABLE 8 RECTAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES

NASAL DRUG DELIVERY

TABLE 9 NASAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES

VAGINAL DRUG DELIVERY

TABLE 10 VAGINAL DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES

OCULAR DRUG DELIVERY

TABLE 11 OCULAR DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES

PULMONARY DRUG DELIVERY

TABLE 12 PULMONARY DRUG DELIVERY, ADVANTAGES AND DISADVANTAGES

CLASSIFICATION OF DRUG DELIVERY BASED ON TECHNOLOGY

SUSTAINED-RELEASE DRUG DELIVERY

TABLE 13 SUSTAINED-RELEASE DELIVERY, ADVANTAGES AND DISADVANTAGES

DELAYED-RELEASE DRUG DELIVERY

TABLE 14 DELAYED-RELEASE DELIVERY, ADVANTAGES AND DISADVANTAGES

PRODRUGS

TABLE 15 PRODRUGS, ADVANTAGES AND DISADVANTAGES

IMPLANTS AND IUDS

TABLE 16 IMPLANTS AND IUDS, ADVANTAGES AND DISADVANTAGES

TARGETED DRUG DELIVERY

Nanoparticles

Liposomes

TABLE 17 LIPOSOMES, ADVANTAGES AND DISADVANTAGES

Polymers

TABLE 18 POLYMERS, ADVANTAGES AND DISADVANTAGES

Monoclonal Antibodies

TABLE 19 MONOCLONAL ANTIBODIES, ADVANTAGES AND DISADVANTAGES

TABLE 20 PEGYLATION, ADVANTAGES AND DISADVANTAGES

CHAPTER FOUR: REGULATORY ISSUES

TABLE 21 FDA-APPROVED DRUGS OF VARIOUS DOSAGE FORMS (2005 TO FEB 2009)

TABLE 22 NUMBER OF NEW APPROVALS FOR DRUG DELIVERY PRODUCTS IN EACH YEAR, 2005- FEB. 2009

FIGURE 1 NUMBER OF NEW APPROVALS FOR DRUG DELIVERY PRODUCTS IN EACH YEAR, 2005 TO FEB. 2009

TABLE 23 APPROVED DRUGS OF VARIOUS DOSAGE FORMS, THROUGH OTHER AGENCIES (2005 TO FEB 2009)

TABLE 24 RECALLS/ SAFETY ALERTS FOR DRUG DELIVERY SYSTEMS (2005 TO FEB. 2009)

CHAPTER FIVE: CLASSIFICATION OF DRUG PRODUCTS BASED ON DRUG DELIVERY TYPE

SUSTAINED-RELEASE ORAL DOSAGE FORMS

TABLE 25 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED-RELEASE ORAL DOSAGE FORMS

SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS

TABLE 26 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS

SUSTAINED-RELEASE TOPICAL DOSAGE FORMS

TABLE 27 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED-RELEASE TOPICAL DOSAGE FORMS

PRODRUGS

TABLE 28 MAJOR SUPPLIERS AND MANUFACTURERS OF PRODRUGS

IMPLANTS AND IUDS

TABLE 29 MAJOR SUPPLIERS AND MANUFACTURERS OF IMPLANTS AND IUDS

TRANSDERMAL DRUG DELIVERY SYSTEMS

TABLE 30 MAJOR SUPPLIERS AND MANUFACTURERS OF TRANSDERMAL DRUG DELIVERY SYSTEMS

LIPOSOMES

TABLE 31 MAJOR SUPPLIERS AND MANUFACTURERS OF LIPOSOMES

NANOPARTICLES

TABLE 32 MAJOR SUPPLIERS AND MANUFACTURERS OF NANOPARTICLES

POLYMERS

TABLE 33 MAJOR SUPPLIERS AND MANUFACTURERS OF POLYMERS

MONOCLONAL ANTIBODIES

TABLE 34 MAJOR SUPPLIERS AND MANUFACTURERS OF MONOCLONAL ANTIBODIES

PEGYNOLOGY

TABLE 35 MAJOR SUPPLIERS AND MANUFACTURERS OF PEGNOLOGY

BUCCAL DRUG DELIVERY SYSTEMS

TABLE 36 MAJOR SUPPLIERS AND MANUFACTURERS OF BUCCAL DRUG DELIVERY SYSTEMS

RECTAL DRUG DELIVERY SYSTEMS

TABLE 37 MAJOR SUPPLIERS AND MANUFACTURERS OF RECTAL DRUG DELIVERY SYSTEMS

VAGINAL DRUG DELIVERY SYSTEMS

TABLE 38 MAJOR SUPPLIERS AND MANUFACTURERS OF VAGINAL DRUG DELIVERY SYSTEMS

OCULAR DRUG DELIVERY SYSTEMS

TABLE 39 MAJOR SUPPLIERS AND MANUFACTURERS OF OCULAR DRUG DELIVERY SYSTEMS

INHALATION SYSTEMS

TABLE 40 MAJOR SUPPLIERS AND MANUFACTURERS OF INHALTION SYSTEMS

CHAPTER SIX: INDUSTRY STRUCTURE

SUSTAINED-RELEASE DOSAGE FORMS

SUSTAINED-RELEASE ORAL DOSAGE FORM

TABLE 41 SHARES OF MANUFACTURERS/SUPPLIERS FOR SUSTAINED-RELEASE ORAL DOSAGE FORMS, 2008 (%)

FIGURE 2 SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED-RELEASE ORAL DOSAGE FORMS, 2008 (%)

SUSTAINED-RELEASE INJECTABLE DOSAGE FORM

TABLE 42 SHARES OF MANUFACTURERS/SUPPLIERS FOR SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS, 2008 (%)

FIGURE 3 SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS, 2008 (%)

SUSTAINED-RELEASE TOPICAL DOSAGE FORM

TABLE 43 SHARES OF MANUFACTURERS/SUPPLIERS FOR SUSTAINED-RELEASE TOPICAL DOSAGE FORMS, 2008 (%)

FIGURE 4 SHARES OF MANUFACTURERS/SUPPLIERS OF SUSTAINED-RELEASE TOPICAL DOSAGE FORMS, 2008 (%)

PRODRUGS

TABLE 44 SHARES OF MANUFACTURERS/SUPPLIERS FOR PRODRUGS, 2008 (%)

FIGURE 5 SHARES OF MANUFACTURERS/SUPPLIERS OF PRODRUGS, 2008 (%)

IMPLANTS AND IUDS

TABLE 45 SHARES OF MANUFACTURERS FOR IMPLANTS AND IUDS, 2008 (%)

FIGURE 6 SHARES OF MANUFACTURERS OF IMPLANTS AND IUDS, 2008 (%)

TRANSDERMAL DRUG DELIVERY SYSTEMS

TABLE 46 SHARES OF MANUFACTURERS/SUPPLIERS FOR TRANSDERMAL DRUG DELIVERY SYSTEMS, 2008 (%)

FIGURE 7 SHARES OF MANUFACTURERS/SUPPLIERS OF TRANSDERMAL DRUG DELIVERY SYSTEMS, 2008 (%)

TARGETED DRUG DELIVERY SYSTEMS

LIPOSOMES

TABLE 47 SHARES OF MANUFACTURERS/SUPPLIERS FOR LIPOSOMES, 2008 (%)

FIGURE 8 SHARES OF MANUFACTURERS/SUPPLIERS OF LIPOSOMES, 2008 (%)

NANOPARTICLES

TABLE 48 SHARES OF MANUFACTURERS/SUPPLIERS FOR NANOPARTICLES, 2008 (%)

FIGURE 9 SHARES OF MANUFACTURERS/SUPPLIERS OF NANOPARTICLES, 2008 (%)

POLYMERS

TABLE 49 SHARES OF MANUFACTURERS/SUPPLIERS FOR POLYMERS, 2008 (%)

FIGURE 10 SHARES OF MANUFACTURERS/SUPPLIERS OF POLYMERS, 2008 (%)

MONOCLONAL ANTIBODIES

TABLE 50 SHARES OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2008 (%)

FIGURE 11 SHARES OF MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2008 (%)

PEGNOLOGY

TABLE 51 SHARES OF MANUFACTURERS/SUPPLIERS FOR PEGNOLOGY, 2008 (%)

FIGURE 12 SHARES OF MANUFACTURERS/SUPPLIERS OF PEGNOLOGY, 2008 (%)

TRANSMUCOSAL DRUG DELIVERY SYSTEMS

BUCCAL DRUG DELIVERY SYSTEMS

TABLE 52 SHARES OF MANUFACTURERS/SUPPLIERS FOR BUCCAL DRUG DELIVERY SYSTEMS, 2008 (%)

FIGURE 13 SHARES OF MANUFACTURERS/ SUPPLIERS OF BUCCAL DRUG DELIVERY SYSTEMS, 2008 (%)

RECTAL DRUG DELIVERY SYSTEMS

TABLE 53 SHARES OF MANUFACTURERS/SUPPLIERS FOR RECTAL DRUG DELIVERY SYSTEMS, 2008 (%)

FIGURE 14 SHARES OF MANUFACTURERS/ SUPPLIERS OF RECTAL DRUG DELIVERY SYSTEMS, 2008 (%)

VAGINAL DRUG DELIVERY SYSTEMS

TABLE 54 SHARES OF MANUFACTURERS/SUPPLIERS FOR VAGINAL DRUG DELIVERY SYSTEMS, 2008 (%)

FIGURE 15 SHARES OF MANUFACTURERS/ SUPPLIERS OF VAGINAL DRUG DELIVERY SYSTEMS, 2008 (%)

OCULAR DRUG DELIVERY SYSTEMS

TABLE 55 SHARES OF MANUFACTURERS/SUPPLIERS FOR OCULAR DRUG DELIVERY SYSTEMS, 2008 (%)

FIGURE 16 SHARES OF MANUFACTURERS/SUPPLIERS OF OCULAR DRUG DELIVERY SYSTEMS, 2008 (%)

INHALATION SYSTEMS

TABLE 56 SHARES OF MANUFACTURERS/SUPPLIERS OF INHALATION SYSTEMS, 2008 (%)

FIGURE 17 SHARES OF MANUFACTURERS/SUPPLIERS OF INHALATION SYSTEMS, 2008 (%)

CHAPTER SEVEN: DEMAND AND USE

OVERALL DRUG DELIVERY MARKET

FACTORS AFFECTING THE DRUG DELIVERY TECHNOLOGY MARKET

PATENT EXPIRATION

TABLE 57 DRUGS WHICH LOST THEIR PATENTS IN 2008

TABLE 58 DRUGS WHICH WILL LOSE THEIR PATENTS IN 2009

DEMAND FOR NEW DRUG DELIVERY TECHNOLOGIES

POOR EFFICACY OF CERTAIN DRUGS

COMPETITION

CHALLENGES FOR DRUG DELIVERY COMPANIES

DEMANDS AND TRENDS

CHAPTER EIGHT: MARKET ANALYSIS

TABLE 59 GLOBAL SALES OF DRUG DELIVERY PRODUCTS, THROUGH 2014 ($ BILLIONS)

FIGURE 18 GLOBAL SALES OF DRUG DELIVERY SYSTEMS, 2007- 2014 ($ BILLIONS)

TABLE 60 MARKET SHARE OF DRUG DELIVERY PRODUCTS, 2008 (%)

FIGURE 19 MARKET SHARE OF DRUG DELIVERY SYSTEM, 2008 (%)

SUSTAINED-RELEASE ORAL DOSAGE FORMS

MARKET SIZE

TABLE 61 GLOBAL SALES OF SUSTAINED-RELEASE ORAL DOSAGE FORMS, THROUGH 2014 ($ MILLIONS)

FIGURE 20 TOTAL GLOBAL SALES OF SUSTAINED-RELEASE ORAL DOSAGE FORMS, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

SUSTAINED-RELEASE INJECTABLE DOSGAE FORM

MARKET SIZE

TABLE 62 GLOBAL SALES OF SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS, THROUGH 2014 ($ MILLIONS)

FIGURE 21 TOTAL GLOBAL SALES OF SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

SUSTAINED-RELEASE TOPICAL DOSAGE FORMS

MARKET SIZE

TABLE 63 GLOBAL SALES OF SUSTAINED-RELEASE TOPICAL DOSAGE FORMS, THROUGH 2014 ($ MILLIONS)

FIGURE 22 TOTAL GLOBAL SALES OF SUSTAINED-RELEASE TOPICAL DOSAGE FORMS, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

PRODRUGS

MARKET SIZE

TABLE 64 TOTAL GLOBAL SALES OF PRODRUGS, THROUGH 2014 ($ MILLIONS)

FIGURE 23 GLOBAL SALES OF PRODRUGS, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

IMPLANTS AND IUDS

MARKET SIZE

TABLE 65 GLOBAL SALES OF IMPLANTS AND IUDS, THROUGH 2014 ($ MILLIONS)

FIGURE 24 TOTAL GLOBAL SALES OF IMPLANTS AND IUDS, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

TRANSDERMAL DRUG DELIVERY

MARKET SIZE

TABLE 66 GLOBAL SALES OF TRANSDERMAL DRUG DELIVERY SYSTEMS, THROUGH 2014 ($ MILLIONS)

FIGURE 25 TOTAL GLOBAL SALES OF TRANSDERMAL DRUG DELIVERY SYSTEMS, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

LIPOSOMES DRUG DELIVERY

MARKET SIZE

TABLE 67 GLOBAL SALES OF LIPOSOMES, THROUGH 2014 ($ MILLIONS)

FIGURE 26 TOTAL GLOBAL SALES OF LIPOSOMES, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

NANOPARTICLES

MARKET SIZE

TABLE 68 GLOBAL SALES OF NANOPARTICLES, THROUGH 2014 ($ MILLIONS)

FIGURE 27 GLOBAL SALES OF NANOPARTICLES, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

POLYMERS

MARKET SIZE

TABLE 69 GLOBAL SALES OF POLYMERS, THROUGH 2014 ($ MILLIONS)

FIGURE 28 GLOBAL SALES OF POLYMERS, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

PEGYLATED DRUG DELIVERY

MARKET SIZE

TABLE 70 GLOBAL SALES OF PEGYLATED DRUG DELIVERY, THROUGH 2014 ($ MILLIONS)

FIGURE 29 TOTAL GLOBAL SALES OF PEGYLATED DRUG DELIVERY, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

MONOCLONAL ANTIBODIES

MARKET SIZE

TABLE 71 GLOBAL SALES OF MONOCLONAL ANTIBODIES, THROUGH 2014 ($ MILLIONS)

FIGURE 30 TOTAL GLOBAL SALES OF MONOCLONAL ANTIBODIES, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

BUCCAL DRUG DELIVERY

MARKET SIZE

TABLE 72 GLOBAL SALES OF BUCCAL DRUG DELIVERY, THOUGH 2014 ($ MILLIONS)

FIGURE 31 TOTAL GLOBAL SALES OF BUCCAL DRUG DELIVERY, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

RECTAL DRUG DELIVERY

MARKET SIZE

TABLE 73 GLOBAL SALES OF RECTAL DRUG DELIVERY, THROUGH 2014 ($ MILLIONS)

FIGURE 32 TOTAL GLOBAL SALES OF RECTAL DRUG DELIVERY, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

OCULAR DRUG DELIVERY

MARKET SIZE

TABLE 74 GLOBAL SALES OF OCULAR DRUG DELIVERY, THROUGH 2014 ($ MILLIONS)

FIGURE 33 TOTAL GLOBAL SALES OF OCULAR DRUG DELIVERY, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

VAGINAL DRUG DELIVERY

MARKET SIZE

TABLE 75 GLOBAL SALES OF VAGINAL DRUG DELIVERY, THROUGH 2014 ($ MILLIONS)

FIGURE 34 TOTAL GLOBAL SALES OF VAGINAL DRUG DELIVERY, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

INHALATION DRUG DELIVERY

MARKET SIZE

TABLE 76 GLOBAL SALES OF INHALATION DRUG DELIVERY, THROUGH 2014 ($ MILLIONS)

FIGURE 35 TOTAL GLOBAL SALES OF INHALATION DRUG DELIVERY, 2007-2014 ($ MILLIONS)

MARKET OVERVIEW

CHAPTER NINE: NEW DEVELOPMENTS

TABLE 77 DEVELOPMENTS IN SUSTAINED-RELEASE ORAL DOSAGE FORMS

TABLE 78 DEVELOPMENTS IN SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS

TABLE 79 DEVELOPMENTS IN SUSTAINED-RELEASE TOPICAL DOSAGE FORMS

TABLE 80 DEVELOPMENTS IN PRODRUGS

TABLE 81 DEVELOPMENTS IN IMPLANTS AND IUDS

TABLE 82 DEVELOPMENTS IN TRANSDERMAL DRUG DELIVERY SYSTEMS

TABLE 83 DEVELOPMENTS IN LIPOSOMAL DELIVERY

TABLE 84 DEVELOPMENTS IN PEGYLATED DRUG DELIVERY

TABLE 85 DEVELOPMENTS IN NANOPARTICLE DRUG DELIVERY

TABLE 86 DEVELOPMENTS IN MONOCLONAL ANTIBODIES

TABLE 87 DEVELOPMENTS IN BUCCAL DRUG DELIVERY

TABLE 88 DEVELOPMENTS IN VAGINAL DRUG DELIVERY

TABLE 89 DEVELOPMENTS IN RECTAL DRUG DELIVERY

TABLE 90 DEVELOPMENTS IN INHALATION DRUG DELIVERY

CHAPTER TEN: MARKET BY THERAPEUTIC AREAS

MARKET SIZE

TABLE 91 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN EACH THERAPEUTIC AREA, THROUGH 2014 ($ BILLIONS)

FIGURE 36 GLOBAL SALES OF DRUGS TO TREAT LIVER DISEASES, 2007-014 ($ BILLIONS)

MARKET SHARE

TABLE 92 SHARE OF DRUG DELIVERY SYSTEMS IN THERAPEUTIC AREAS, 2008 (%)

FIGURE 37 SHARE OF DRUG DELIVERY SYSTEMS IN THERAPEUTIC AREAS, 2008 (%)

CARDIOVASCULAR DISEASES

MARKET SIZE

TABLE 93 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CARDIOVASCULAR DISEASES, THROUGH 2004 ($ BILLIONS)

FIGURE 38 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CARDIOVASCULAR DISEASES, 2007-2014 ($ BILLIONS)

ONCOLOGY

MARKET SIZE

TABLE 94 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN ONCOLOGY, THROUGH 2014 ($ BILLIONS)

FIGURE 39 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN ONCOLOGY, 2007-2014 ($ BILLIONS)

GASTROINTESTINAL

MARKET SIZE

TABLE 95 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN GASTROINTESTINAL DISORDERS, THROUGH 2014 ($ BILLIONS)

FIGURE 40 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN GASTROINTESTINAL DISORDERS, 2007-2014 ($ BILLIONS)

UROLOGY

MARKET SIZE

TABLE 96 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN UROLOGY, THROUGH 2014 ($ BILLIONS)

FIGURE 41 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN UROLOGY, 2007-2014 ($ BILLIONS)

DIABETES

MARKET SIZE

TABLE 97 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN DIABETIC MARKET, THROUGH 2014 ($ BILLIONS)

FIGURE 42 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN DIABETIC MARKET, 2007-2014 ($ BILLIONS)

CENTRAL NERVOUS SYSTEM DISORDER

MARKET SIZE

TABLE 98 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CENTERAL NERVOUS SYSTEM MARKET, THROUGH 2014 ($ BILLIONS)

FIGURE 42 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN CENTRAL NERVOUS SYSTEM MARKET, 2007-2014 ($ BILLIONS)

RESPIRATORY DRUG DELIVERY SYSTEMS

MARKET SIZE

TABLE 99 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN RESPIRATORY DISEASES, THROUGH 2014 ($ BILLIONS)

FIGURE 44 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN RISPIRATORY DISEASES, 2007-2014 ($ BILLIONS)

INFLAMMATORY DISEASES AND ALLERGY

MARKET SIZE

TABLE 100 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN INFLAMMATORY AND ALLERGY, 2007-2014 ($ BILLIONS)

FIGURE 45 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN INFLAMMATORY AND ALLERGY DISEASES, 2007-2014 ($ BILLIONS)

OPHTHALMOLOGY

MARKET SIZE

TABLE 101 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, THROUGH 2014 ($ BILLIONS)

FIGURE 46 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, 2007-2014 ($ BILLIONS)

VIRAL AND BACTERIAL DISEASES

MARKET SIZE

TABLE 102 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN VIRAL AND BACTERIAL DISEASES, THROUGH 2014 ($ BILLIONS).... 132

FIGURE 47 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN VIRAL AND BACTERIAL DISEASES, 2007-2014 ($ BILLIONS)

HORMONE REPLACEMENT THERAPY (HRT) AND GYNECOLOGY .... 132

MARKET SIZE

TABLE 103 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN HORMONE REPLACEMENT THERAPY AND GYNECOLOGY, THROUGH 2014 ($ BILLIONS)

FIGURE 48 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN HORMONE REPLACEMENT THERAPY AND GYNECOLOGY, 2007-2014 ($ BILLIONS)

OTHERS

MARKET SIZE

TABLE 104 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OTHER THERAPEUTIC AREAS AND TECHNOLOGIES, THROUGH 2014 ($ BILLIONS)

FIGURE 49 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OTHER THERAPEUTIC AREAS AND TECHNOLOGIES, 2007-2014 ($ BILLIONS)

CHAPTER ELEVEN: PATENT ANALYSIS

PATENTS BY YEAR

TABLE 105 TOTAL NUMBER OF PATENTS IN EACH YEAR, 2005-2009

FIGURE 50 NUMBER OF PATENTS, 2005-2009

PATENTS BY TYPE

TABLE 106 NUMBER OF PATENTS BY TYPE, 2005-2009

FIGURE 51 NUMBER OF PATENTS BY TYPE, 2005-2009

FIGURE 52 TOTAL NUMBER OF PATENTS, SHARE BY TYPE, 2005-2009 (%)

PATENTS BY COUNTRY

TABLE 107 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2009

FIGURE 53 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2009

PATENTS BY COMPANY

TABLE 108 NUMBER OF PATENTS BY COMPANY, 2005-2009

FIGURE 54 NUMBER OF PATENTS BY COMPANY, 2005-2009

PATENTS BY ASSIGNEE

TABLE 109 NUMBER OF PATENTS BY ASSIGNEE, 2005-2009

FIGURE 55 NUMBER OF PATENTS BY ASSIGNEE, 2005-2009

CHAPTER TWELVE: COMPANY PROFILES

ABBOTT LABORATORIES

ABRAXIS BIOSCIENCE, INC.

AKELA PHARMA

AKORN, INC

ALCON, INC.

ALEXION PHARMACEUTICALS

ALKERMES, INC.

ALLERGAN

ALPHARX

AMGEN

ANTIGENICS

A P PHARMA

ASTELLAS PHARMA

ASTRAZENECA

ATON PHARMA

BARR PHARMACEUTICALS, INC.

BAXTER

BAYER HEALTHCARE

BIOGEN IDEC

BIOSANTE PHARMACEUTICALS, INC

BIOVAIL

BOEHRINGER INGELHEIM

BRISTOL MYERS SQUIBB

CENTOCOR

CEPHALON INC.

COLUMBIA LABS

DIATOS SA

EISAI CO

ELAN

ENZON

EURAND N.V

GENENTECH

GENEREX BIOTECH

GENZYME

GILEAD SCIENCES, INC

GLAXOSMITHKLINE PLC

IMCLONE SYSTEMS

JOHNSON AND JOHNSON

KING PHARMACEUTICALS

K.V. PHARMACEUTICAL CO

LAVIPHARM CORPORATION

3M COMPANY

MERCK & CO.

MYLAN LABORATORIES, INC.

NEKTAR THERAPEUTICS

NOVEN PHARMACEUTICALS, INC

NOVARTIS AG

NOVAVAX, INC

NYCOMED US, INC

OSI PHARMACEUTICALS, INC

PAR PHARMACEUTICAL COMPANIES, INC.

PDL BIOPHARMA, INC

PFIZER INC

QLT, INC

ROCHE

SANOFI-AVENTIS

SCHERING-PLOUGH

TEVA PHARMACEUTICAL INDUSTRIES, LTD.

WATSON PHARMACEUTICALS, INC

WYETH, INC.

APPENDIX: ABBREVIATIONS

ABBREVIATIONS

LIST OF TABLES

SUMMARY TABLE GLOBAL SALES FOR DRUG DELIVERY PRODUCTS,

THROUGH 2014 ($ BILLIONS)

TABLE 1 GASEOUS DOSAGE FORMS, ADVANTAGES AND

DISADVANTAGES

TABLE 2 LIQUID DOSAGE FORMS, ADVANTAGES AND

DISADVANTAGES

TABLE 3 SEMISOLID DOSAGE FORMS, ADVANTAGES AND

DISADVANTAGES

TABLE 4 SOLID DOSAGE FORMS, ADVANTAGES AND

DISADVANTAGES

TABLE 5 TOPICAL DRUG DELIVERY, ADVANTAGES AND

DISADVANTAGES

TABLE 6 ORAL DRUG DELIVERY, ADVANTAGES AND

DISADVANTAGES

TABLE 7 INJECTABLE OR PARENTERAL DRUG DELIVERY,

ADVANTAGES AND DISADVANTAGES

TABLE 8 RECTAL DRUG DELIVERY, ADVANTAGES AND

DISADVANTAGES

TABLE 9 NASAL DRUG DELIVERY, ADVANTAGES AND

DISADVANTAGES

TABLE 10 VAGINAL DRUG DELIVERY, ADVANTAGES AND

DISADVANTAGES

TABLE 11 OCULAR DRUG DELIVERY, ADVANTAGES AND

DISADVANTAGES

TABLE 12 PULMONARY DRUG DELIVERY, ADVANTAGES AND

DISADVANTAGES

TABLE 13 SUSTAINED-RELEASE DELIVERY, ADVANTAGES AND

DISADVANTAGES

TABLE 14 DELAYED-RELEASE DELIVERY, ADVANTAGES AND

DISADVANTAGES

TABLE 15 PRODRUGS, ADVANTAGES AND DISADVANTAGES

TABLE 16 IMPLANTS AND IUDS, ADVANTAGES AND

DISADVANTAGES

TABLE 17 LIPOSOMES, ADVANTAGES AND DISADVANTAGES

TABLE 18 POLYMERS, ADVANTAGES AND DISADVANTAGES

TABLE 19 MONOCLONAL ANTIBODIES, ADVANTAGES AND

DISADVANTAGES

TABLE 20 PEGYLATION, ADVANTAGES AND DISADVANTAGES

TABLE 21 FDA-APPROVED DRUGS OF VARIOUS DOSAGE FORMS

(2005 TO FEB 2009)

TABLE 22 NUMBER OF NEW APPROVALS FOR DRUG DELIVERY

PRODUCTS IN EACH YEAR, 2005- FEB. 2009

TABLE 23 APPROVED DRUGS OF VARIOUS DOSAGE FORMS,

THROUGH OTHER AGENCIES (2005 TO FEB 2009)

TABLE 24 RECALLS/ SAFETY ALERTS FOR DRUG DELIVERY

SYSTEMS (2005 TO FEB. 2009)

TABLE 25 MAJOR SUPPLIERS AND MANUFACTURERS OF

SUSTAINED-RELEASE ORAL DOSAGE FORMS

TABLE 26 MAJOR SUPPLIERS AND MANUFACTURERS OF

SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS

TABLE 27 MAJOR SUPPLIERS AND MANUFACTURERS OF

SUSTAINED-RELEASE TOPICAL DOSAGE FORMS

TABLE 28 MAJOR SUPPLIERS AND MANUFACTURERS OF PRODRUGS

TABLE 29 MAJOR SUPPLIERS AND MANUFACTURERS OF IMPLANTS

AND IUDS

TABLE 30 MAJOR SUPPLIERS AND MANUFACTURERS OF

TRANSDERMAL DRUG DELIVERY SYSTEMS

TABLE 31 MAJOR SUPPLIERS AND MANUFACTURERS OF

LIPOSOMES

TABLE 32 MAJOR SUPPLIERS AND MANUFACTURERS OF

NANOPARTICLES

TABLE 33 MAJOR SUPPLIERS AND MANUFACTURERS OF POLYMERS

TABLE 34 MAJOR SUPPLIERS AND MANUFACTURERS OF

MONOCLONAL ANTIBODIES

TABLE 35 MAJOR SUPPLIERS AND MANUFACTURERS OF

PEGNOLOGY

TABLE 36 MAJOR SUPPLIERS AND MANUFACTURERS OF BUCCAL

DRUG DELIVERY SYSTEMS

TABLE 37 MAJOR SUPPLIERS AND MANUFACTURERS OF RECTAL

DRUG DELIVERY SYSTEMS

TABLE 38 MAJOR SUPPLIERS AND MANUFACTURERS OF VAGINAL

DRUG DELIVERY SYSTEMS

TABLE 39 MAJOR SUPPLIERS AND MANUFACTURERS OF OCULAR

DRUG DELIVERY SYSTEMS

TABLE 40 MAJOR SUPPLIERS AND MANUFACTURERS OF

INHALTION SYSTEMS

TABLE 41 SHARES OF MANUFACTURERS/SUPPLIERS FOR

SUSTAINED-RELEASE ORAL DOSAGE FORMS, 2008 (%)

TABLE 42 SHARES OF MANUFACTURERS/SUPPLIERS FOR

SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS, 2008 (%)

TABLE 43 SHARES OF MANUFACTURERS/SUPPLIERS FOR

SUSTAINED-RELEASE TOPICAL DOSAGE FORMS, 2008 (%)

TABLE 44 SHARES OF MANUFACTURERS/SUPPLIERS FOR

PRODRUGS, 2008 (%)

TABLE 45 SHARES OF MANUFACTURERS/SUPPLIERS FOR IMPLANTS

AND IUDS, 2008 (%)

TABLE 46 SHARES OF MANUFACTURERS/SUPPLIERS FOR

TRANSDERMAL DRUG DELIVERY SYSTEMS, 2008 (%)

TABLE 47 SHARES OF MANUFACTURERS/SUPPLIERS FOR

LIPOSOMES, 2008 (%)

TABLE 48 SHARES OF MANUFACTURERS/SUPPLIERS FOR

NANOPARTICLES, 2008 (%)

TABLE 49 SHARES OF MANUFACTURERS/SUPPLIERS FOR

POLYMERS, 2008 (%)

TABLE 50 SHARES OF MANUFACTURERS/SUPPLIERS FOR

MONOCLONAL ANTIBODIES, 2008 (%)

TABLE 51 SHARES OF MANUFACTURERS FOR PEGNOLOGY, 2008 (%)

TABLE 52 SHARES OF MANUFACTURERS/SUPPLIERS FOR BUCCAL

DRUG DELIVERY SYSTEMS, 2008 (%)

TABLE 53 SHARES OF MANUFACTURERS/SUPPLIERS FOR RECTAL

DRUG DELIVERY SYSTEMS, 2008 (%)

TABLE 54 SHARES OF MANUFACTURERS/SUPPLIERS FOR VAGINAL

DRUG DELIVERY SYSTEMS, 2008 (%)

TABLE 55 SHARES OF MANUFACTURERS/SUPPLIERS FOR OCULAR

DRUG DELIVERY SYSTEMS, 2008 (%)

TABLE 56 SHARES OF MANUFACTURERS/SUPPLIERS FOR

INHALATION SYSTEMS, 2008 (%)

TABLE 57 DRUGS WHICH LOST THEIR PATENTS IN 2008

TABLE 58 DRUGS WHICH WILL LOSE THEIR PATENTS IN 2009

TABLE 59 GLOBAL SALES OF DRUG DELIVERY PRODUCTS,

THROUGH 2014 ($ BILLIONS)

TABLE 60 MARKET SHARE OF DRUG DELIVERY PRODUCTS, 2008 (%)

TABLE 61 GLOBAL SALES OF SUSTAINED-RELEASE ORAL DOSAGE

FORMS, THROUGH 2014 ($ MILLIONS)

TABLE 62 GLOBAL SALES OF SUSTAINED-RELEASE INJECTABLE

DOSAGE FORMS, THROUGH 2014 ($ MILLIONS)

TABLE 63 GLOBAL SALES OF SUSTAINED-RELEASE TOPICAL

DOSAGE FORMS, THROUGH 2014 ($ MILLIONS)

TABLE 64 TOTAL GLOBAL SALES OF PRODRUGS, THROUGH 2014 ($

MILLIONS)

TABLE 65 GLOBAL SALES OF IMPLANTS AND IUDS, THROUGH 2014

($ MILLIONS)

TABLE 66 GLOBAL SALES OF TRANSDERMAL DRUG DELIVERY

SYSTEMS, THROUGH 2014 ($ MILLIONS)

TABLE 67 GLOBAL SALES OF LIPOSOMES, THROUGH 2014 ($

MILLIONS)

TABLE 68 GLOBAL SALES OF NANOPARTICLES, THROUGH 2014 ($

MILLIONS)

TABLE 69 GLOBAL SALES OF POLYMERS, THROUGH 2014 ($

MILLIONS)

TABLE 70 GLOBAL SALES OF PEGYLATED DRUG DELIVERY,

THROUGH 2014 ($ MILLIONS)

TABLE 71 GLOBAL SALES OF MONOCLONAL ANTIBODIES,

THROUGH 2014 ($ MILLIONS)

TABLE 72 GLOBAL SALES OF BUCCAL DRUG DELIVERY, THOUGH

2014 ($ MILLIONS)

TABLE 73 GLOBAL SALES OF RECTAL DRUG DELIVERY, THROUGH

2014 ($ MILLIONS)

TABLE 74 GLOBAL SALES OF OCULAR DRUG DELIVERY, THROUGH

2014 ($ MILLIONS)

TABLE 75 GLOBAL SALES OF VAGINAL DRUG DELIVERY, THROUGH

2014 ($ MILLIONS)

TABLE 76 GLOBAL SALES OF INHALATION DRUG DELIVERY,

THROUGH 2014 ($ MILLIONS)

TABLE 77 DEVELOPMENTS IN SUSTAINED-RELEASE ORAL DOSAGE

FORMS

TABLE 78 DEVELOPMENTS IN SUSTAINED-RELEASE INJECTABLE

DOSAGE FORMS

TABLE 79 DEVELOPMENTS IN SUSTAINED-RELEASE TOPICAL

DOSAGE FORMS

TABLE 80 DEVELOPMENTS IN PRODRUGS

TABLE 81 DEVELOPMENTS IN IMPLANTS AND IUDS

TABLE 82 DEVELOPMENTS IN TRANSDERMAL DRUG DELIVERY

SYSTEMS

TABLE 83 DEVELOPMENTS IN LIPOSOMAL DELIVERY

TABLE 84 DEVELOPMENTS IN PEGYLATED DRUG DELIVERY

TABLE 85 DEVELOPMENTS IN NANOPARTICLE DRUG DELIVERY

TABLE 86 DEVELOPMENTS IN MONOCLONAL ANTIBODIES

TABLE 87 DEVELOPMENTS IN BUCCAL DRUG DELIVERY

TABLE 88 DEVELOPMENTS IN VAGINAL DRUG DELIVERY

TABLE 89 DEVELOPMENTS IN RECTAL DRUG DELIVERY

TABLE 90 DEVELOPMENTS IN INHALATION DRUG DELIVERY

TABLE 91 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN EACH

THERAPEUTIC AREA, THROUGH 2014 ($ BILLIONS)

TABLE 92 SHARE OF DRUG DELIVERY SYSTEMS IN THERAPEUTIC

AREAS, 2008 (%)

TABLE 93 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN

CARDIOVASCULAR DISEASES, THROUGH 2004 ($ BILLIONS)

TABLE 94 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN

ONCOLOGY, THROUGH 2014 ($ BILLIONS)

TABLE 95 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN

GASTROINTESTINAL DISORDERS, THROUGH 2014 ($ BILLIONS)

TABLE 96 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN

UROLOGY, THROUGH 2014 ($ BILLIONS)

TABLE 97 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN

DIABETIC MARKET, THROUGH 2014 ($ BILLIONS)

TABLE 98 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN

CENTERAL NERVOUS SYSTEM MARKET, THROUGH 2014 ($

BILLIONS)

TABLE 99 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN

RESPIRATORY DISEASES, THROUGH 2014 ($ BILLIONS)

TABLE 100 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN

INFLAMMATORY AND ALLERGY, 2007-2014 ($ BILLIONS)

TABLE 101 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN

OPHTHALMOLOGY, THROUGH 2014 ($ BILLIONS)

TABLE 102 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN VIRAL

AND BACTERIAL DISEASES, THROUGH 2014 ($ BILLIONS)

TABLE 103 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN

HORMONE REPLACEMENT THERAPY AND GYNECOLOGY,

THROUGH 2014 ($ BILLIONS)

TABLE 104 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OTHER

THERAPEUTIC AREAS AND TECHNOLOGIES, THROUGH 2014 ($

BILLIONS)

TABLE 105 TOTAL NUMBER OF PATENTS IN EACH YEAR, 2005-2009

TABLE 106 NUMBER OF PATENTS BY TYPE, 2005-2009

TABLE 107 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2009

TABLE 108 NUMBER OF PATENTS BY COMPANY, 2005-2009

TABLE 109 NUMBER OF PATENTS BY ASSIGNEE, 2005-2009

LIST OF FIGURES

SUMMARY FIGURE GLOBAL SALES FOR DRUG DELIVERY

PRODUCTS, 2007-2014 ($ BILLIONS)

FIGURE 1 NUMBER OF NEW APPROVALS FOR DRUG DELIVERY

PRODUCTS IN EACH YEAR, 2005 TO FEB. 2009

FIGURE 2 SHARES OF MANUFACTURERS/SUPPLIERS OF

SUSTAINED-RELEASE ORAL DOSAGE FORMS, 2008 (%)

FIGURE 3 SHARES OF MANUFACTURERS/SUPPLIERS OF

SUSTAINED-RELEASE INJECTABLE DOSAGE FORMS, 2008 (%)

FIGURE 4 SHARES OF MANUFACTURERS/SUPPLIERS OF

SUSTAINED-RELEASE TOPICAL DOSAGE FORMS, 2008 (%)

FIGURE 5 SHARES OF MANUFACTURERS/SUPPLIERS OF PRODRUGS,

2008 (%)

FIGURE 6 SHARES OF MANUFACTURERS OF IMPLANTS AND IUDS,

2008 (%)

FIGURE 7 SHARES OF MANUFACTURERS/SUPPLIERS OF

TRANSDERMAL DRUG DELIVERY SYSTEMS, 2008 (%)

FIGURE 8 SHARES OF MANUFACTURERS/SUPPLIERS OF

LIPOSOMES, 2008 (%)

FIGURE 9 SHARES OF MANUFACTURERS/SUPPLIERS OF

NANOPARTICLES, 2008 (%)

FIGURE 10 SHARES OF MANUFACTURERS/SUPPLIERS OF

POLYMERS, 2008 (%)

FIGURE 11 SHARES OF MANUFACTURERS/SUPPLIERS OF

MONOCLONAL ANTIBODIES, 2008 (%)

FIGURE 12 SHARES OF MANUFACTURERS/SUPPLIERS OF

PEGNOLOGY, 2008 (%)

FIGURE 13 SHARES OF MANUFACTURERS/ SUPPLIERS OF BUCCAL

DRUG DELIVERY SYSTEMS, 2008 (%)

FIGURE 14 SHARES OF MANUFACTURERS/ SUPPLIERS OF RECTAL

DRUG DELIVERY SYSTEMS, 2008 (%)

FIGURE 15 SHARES OF MANUFACTURERS/ SUPPLIERS OF VAGINAL

DRUG DELIVERY SYSTEMS, 2008 (%)

FIGURE 16 SHARES OF MANUFACTURERS/SUPPLIERS OF OCULAR

DRUG DELIVERY SYSTEMS, 2008 (%)

FIGURE 17 SHARES OF MANUFACTURERS/SUPPLIERS OF

INHALATION SYSTEMS, 2008 (%)

FIGURE 18 GLOBAL SALES OF DRUG DELIVERY SYSTEMS, 2007-2014

($ BILLIONS)

FIGURE 19 MARKET SHARE OF DRUG DELIVERY SYSTEM, 2008 (%)

FIGURE 20 TOTAL GLOBAL SALES OF SUSTAINED-RELEASE ORAL

DOSAGE FORMS, 2007-2014 ($ MILLIONS)

FIGURE 21 TOTAL GLOBAL SALES OF SUSTAINED-RELEASE

INJECTABLE DOSAGE FORMS, 2007-2014 ($ MILLIONS)

FIGURE 22 TOTAL GLOBAL SALES OF SUSTAINED-RELEASE

TOPICAL DOSAGE FORMS, 2007-2014 ($ MILLIONS)

FIGURE 23 GLOBAL SALES OF PRODRUGS, 2007-2014 ($ MILLIONS)

FIGURE 24 TOTAL GLOBAL SALES OF IMPLANTS AND IUDS, 2007-

2014 ($ MILLIONS)

FIGURE 25 TOTAL GLOBAL SALES OF TRANSDERMAL DRUG

DELIVERY SYSTEMS, 2007-2014 ($ MILLIONS)

FIGURE 26 TOTAL GLOBAL SALES OF LIPOSOMES, 2007-2014 ($

MILLIONS)

FIGURE 27 GLOBAL SALES OF NANOPARTICLES, 2007-2014 ($

MILLIONS)

FIGURE 28 GLOBAL SALES OF POLYMERS, 2007-2014 ($ MILLIONS)

FIGURE 29 TOTAL GLOBAL SALES OF PEGYLATED DRUG DELIVERY,

2007-2014 ($ MILLIONS)

FIGURE 30 TOTAL GLOBAL SALES OF MONOCLONAL ANTIBODIES,

2007-2014 ($ MILLIONS)

FIGURE 31 TOTAL GLOBAL SALES OF BUCCAL DRUG DELIVERY,

2007-2014 ($ MILLIONS)

FIGURE 32 TOTAL GLOBAL SALES OF RECTAL DRUG DELIVERY,

2007-2014 ($ MILLIONS)

FIGURE 33 TOTAL GLOBAL SALES OF OCULAR DRUG DELIVERY,

2007-2014 ($ MILLIONS)

FIGURE 34 TOTAL GLOBAL SALES OF VAGINAL DRUG DELIVERY,

2007-2014 ($ MILLIONS)

FIGURE 35 TOTAL GLOBAL SALES OF INHALATION DRUG

DELIVERY, 2007-2014 ($ MILLIONS)

FIGURE 36 GLOBAL SALES OF DRUGS TO TREAT LIVER DISEASES,

2007-014 ($ BILLIONS)

FIGURE 37 SHARE OF DRUG DELIVERY SYSTEMS IN THERAPEUTIC

AREAS, 2008 (%)

FIGURE 38 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN

CARDIOVASCULAR DISEASES, 2007-2014 ($ BILLIONS)

FIGURE 39 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN

ONCOLOGY, 2007-2014 ($ BILLIONS)

FIGURE 40 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN

GASTROINTESTINAL DISORDERS, 2007-2014 ($ BILLIONS)

FIGURE 41 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN

UROLOGY, 2007-2014 ($ BILLIONS)

FIGURE 42 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN

DIABETIC MARKET, 2007-2014 ($ BILLIONS)

FIGURE 42 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN

CENTRAL NERVOUS SYSTEM MARKET, 2007-2014 ($ BILLIONS)

FIGURE 44 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN

RISPIRATORY DISEASES, 2007-2014 ($ BILLIONS)

FIGURE 45 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN

INFLAMMATORY AND ALLERGY DISEASES, 2007-2014 ($ BILLIONS) .... 129

FIGURE 46 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN

OPHTHALMOLOGY, 2007-2014 ($ BILLIONS)

FIGURE 47 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN VIRAL

AND BACTERIAL DISEASES, 2007-2014 ($ BILLIONS)

FIGURE 48 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN

HORMONE REPLACEMENT THERAPY AND GYNECOLOGY, 2007-

2014 ($ BILLIONS)

FIGURE 49 GLOBAL SALES OF DRUG DELIVERY SYSTEMS IN OTHER

THERAPEUTIC AREAS AND TECHNOLOGIES, 2007-2014 ($

BILLIONS)

FIGURE 50 NUMBER OF PATENTS, 2005-2009

FIGURE 51 NUMBER OF PATENTS BY TYPE, 2005-2009

FIGURE 52 TOTAL NUMBER OF PATENTS, SHARE BY TYPE, 2005-2009

(%)

FIGURE 53 TOTAL NUMBER OF PATENTS BY COUNTRY, 2005-2009

FIGURE 54 NUMBER OF PATENTS BY COMPANY, 2005-2009

FIGURE 55 NUMBER OF PATENTS BY ASSIGNEE, 2005-2009

Abstract

• The global market for advanced drug delivery systems amounted to $134.3 billion in 2008, and was projected to increase to $139 billion in 2009. The estimate for 2014 is $196.4 billion, for a compound annual growth rate (CAGR) of 7.2% in the 5-year period.
• The largest segment of the market is targeted drug delivery, which reached $50.9 billion in 2009 and is expected to increase to $80.2 billion in 2014, for a CAGR of 9.5%.
• Sustained-release products have the second-largest market share, with estimated sales of $36.1 billion in 2009 and $45.8 billion in 2014, for a CAGR of 4.9%.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.